Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 188,888 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $14.97, for a total value of $2,827,653.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Wednesday, March 20th, Andrew Dudum sold 50,361 shares of Hims & Hers Health stock. The stock was sold at an average price of $16.34, for a total transaction of $822,898.74.
• On Tuesday, February 13th, Andrew Dudum sold 97,208 shares of Hims & Hers Health stock. The shares were sold at an average price of $9.58, for a total transaction of $931,252.64.
• On Monday, January 29th, Andrew Dudum sold 15,100 shares of Hims & Hers Health stock. The stock was sold at an average price of $9.01, for a total value of $136,051.00.
• On Thursday, January 25th, Andrew Dudum sold 127,688 shares of Hims & Hers Health stock. The shares were sold at an average price of $9.08, for a total value of $1,159,407.04.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $14.88 on Tuesday. The company has a market capitalization of $3.19 billion, a price-to-earnings ratio of -135.27 and a beta of 0.91. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $17.16. The firm has a 50-day simple moving average of $12.76 and a 200-day simple moving average of $9.44.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. The company had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The company’s revenue was up 47.4% on a year-over-year basis. During the same period last year, the business posted ($0.05) EPS. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.1 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Leerink Partnrs reiterated a “market perform” rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Guggenheim increased their price objective on Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. TheStreet upgraded Hims & Hers Health from a “d” rating to a “c” rating in a research note on Monday, March 4th. Piper Sandler increased their price target on shares of Hims & Hers Health from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Tuesday, February 27th. Finally, Citigroup raised their price objective on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $13.45.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently made changes to their positions in the company. CM Wealth Advisors LLC purchased a new position in Hims & Hers Health during the second quarter worth about $25,000. Point72 Middle East FZE purchased a new position in Hims & Hers Health in the 4th quarter valued at about $29,000. Captrust Financial Advisors boosted its stake in shares of Hims & Hers Health by 1,827.4% during the 1st quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock worth $36,000 after purchasing an additional 6,414 shares during the last quarter. Harbour Investments Inc. grew its holdings in shares of Hims & Hers Health by 427.9% during the third quarter. Harbour Investments Inc. now owns 6,995 shares of the company’s stock worth $44,000 after buying an additional 5,670 shares in the last quarter. Finally, Belpointe Asset Management LLC acquired a new position in shares of Hims & Hers Health in the first quarter valued at approximately $46,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.